Skip to main content

Janus Henderson Investors — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

229
Companies
$32.5B
Total invested
$163.9M
Avg. check
45
Industries
Biotechnology 17Health Care 13Therapeutics 10Pharmaceutical 6Life Science 6Biopharma 6+39 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 229
Encoded Therapeutics
September 2026

Encoded Therapeutics is a biotechnology company developing genetic medicines for neurological disorders and other diseases.

Biotechnology · South San Francisco$275.0M Series F
Helus Pharma
September 2026

Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

Biotechnology · Toronto$50.0M Post-IPO Equity
Xos Trucks
September 2025

Xos Trucks specializes in the field of manufacturing fully electric commercial vehicles.

Business Development · Los Angeles$2.4M Post-IPO Equity
Aktis Oncology
September 2024

Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.

Biotechnology · Boston$175.0M Series B
Pyxis Oncology
September 2026

Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.

Biotechnology · Boston$110.0M Post-IPO Equity
AN2 Therapeutics
September 2026

AN2 Therapeutics develops small-molecule medicines from boron chemistry for infectious diseases, hematologic disorders, and oncology.

Biotechnology · Menlo Park$40.0M Grant
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post-IPO Equity
Monopar
September 2025

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

Biopharma · Wilmette$135.0M Post-IPO Equity
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post-IPO Equity
Tare
September 2026

Tare uses AI and tokenization to change the entire credit lifecycle.

Artificial Intelligence (AI) · Brooklyn$13.3M Seed
Tyra Biosciences
September 2026

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$400.0M Post-IPO Equity
Loadsmart
September 2022

Loadsmart is the end-to-end AI freight platform for shippers with embedded operational services.

Enterprise Software · ChicagoUndisclosed
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post-IPO Equity
QuantumScape
August 2023

QuantumScape develops solid-state lithium-metal batteries for electric vehicles and other energy storage applications.

Automotive · San Jose$300.0M Post-IPO Equity
Bigfoot Biomedical
August 2022

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes.

Artificial Intelligence (AI) · MilpitasConvertible Note
Inspirato
August 2024

Inspirato is a luxury travel and lifestyle subscription company.

Lifestyle · Denver$4.6M Post-IPO Equity
Compass Therapeutics
August 2025

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

Biopharma · Boston$120.0M Post-IPO Equity
Epicrispr Biotechnologies
August 2026

Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.

Biotechnology · South San Francisco$90.0M Series C
Annexon Biosciences
July 2026

Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.

Biotechnology · South San Francisco$50.0M Post-IPO Debt
Day One Biopharmaceuticals
July 2024

Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.

Biopharma · South San Francisco$175.0M Post-IPO Equity
Claris Biotherapeutics
July 2026

Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.

Biopharma · Jersey City$118.0M Series B
Wallbox
July 2026

Wallbox is a technology company that provides electric vehicle charging and energy management solutions.

Automotive · Barcelona$4.6M Post-IPO Equity
Scorpion Therapeutics
July 2024

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Biotechnology · Boston$150.0M Series C
Draig Therapeutics
July 2026

Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders.

Biopharma · Cardiff$65.0M Series B

Where Janus Henderson Investors invests

Biotechnology17
Health Care13
Therapeutics10
Pharmaceutical6
Life Science6
Biopharma6

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?▸

Janus Henderson Investors has invested in 229 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?▸

Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Life Science. The firm invests across 45 different industry categories.

What is Janus Henderson Investors's largest investment?▸

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $32.5B.

What is the average investment size for Janus Henderson Investors?▸

Janus Henderson Investors's average investment size is $163.9M across its portfolio of 229 companies.

What are Janus Henderson Investors's most recent investments?▸

Recent Janus Henderson Investors portfolio additions include Encoded Therapeutics, Helus Pharma, Xos Trucks, Aktis Oncology, Pyxis Oncology. These companies were founded in 2020 or later.

Reach the founders behind these 229 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →